curasan AG

  • ISIN: DE000A2YPGM4
  • Land: Deutschland

Nachricht vom 01.10.2019 | 14:48

curasan launches product for the treatment of the spinal facet syndrome

DGAP-Media / 01.10.2019 / 14:48

curasan launches product for the treatment of the spinal facet syndrome

- curasan receives CE clearance for Spinevisc(R) Hyaluronic Acid for the treatment of spinal facet joint arthrosis

- Extended reach to new target groups in the Spine, Neuroradiology and Interventional Pain Therapy market

Kleinostheim, October 1st, 2019 - curasan AG, Germany, a leading specialist for medical products in the field of orthobiologics and interventional pain management, launches Spinevisc(R), a biomimetic hyaluronic acid with a medium molecular weight similar to the body's own synovial fluids, dedicated for the treatment of the widespread facet syndrome (facet joint arthrosis).

"The launch of Spinevisc(R) sets another milestone in the history of curasan", states Torben Sorensen, new CEO of curasan. "Despite the currently challenging market and regulatory environment, our interdisciplinary team of Marketing, Medical Affairs and Regulatory specialists have managed to bring a product to market that is dedicated to treat the painful symptoms of the widespread facet syndrome."

"Spinevisc(R) will allow curasan to extend its reach and to address new target groups such as specialized Neuroradiologists and Interventional Pain Therapists, as well as Spine surgeons, thus allowing the company in entering entirely new distribution channels and an untouched market segment", states Gregor Siebert, Director of Marketing and Sales.

"With over a decade experience in arthrosis management with curasan's proprietary hyaluronic acid formula, it was a logical step for us to further focus on how we could possibly address the needs of a minimally-invasive, yet safe and easy-to-apply solution in treating back pain caused by the facet syndrome", adds Florian Früh, Head of Product Management.

curasan will launch Spinevisc(R) during the German Orthopedic and Traumatology Congress (DKOU), to be held between October 22-25 in Berlin, Germany, followed by the Spine Interventional Neuroradiology Symposium of the European Society of Neuroradiology (ESNR), to be held from October 25-27 in Malta.

Contact curasan AG:
Andrea Weidner
IR & Corporate Communications

Contact for product related requests:
Florian Früh
Head of Product Management

About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan.

End of Media Release

Issuer: curasan AG
Key word(s): Health

01.10.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)


Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

Uzin Utz AG

Original-Research: Uzin Utz AG (von Montega AG): Kaufen

15. November 2019